StockData
CannaPharmaRx, Inc. logo

CannaPharmaRx, Inc. (CPMD) stock

CPMDOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 1/30
$0.00+0.00 (0.00%)

Close on Oct 16, 2026Market cap $2.54MP/E –Yield –

CannaPharmaRx operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

CannaPharmaRx's operating income for the twelve months ending Sep 30, 2026 was -$2.49M. For fiscal 2025 it was -$3.35M. The highest annual figure on record is $585.60K in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.35M–
FY2024Dec 31, 2024-$3.63M–
FY2023Dec 31, 2023-$1.58M–
FY2022Dec 31, 2022-$5.21M–
FY2021Dec 31, 2021-$2.99M–
FY2020Dec 31, 2020-$14.49M–
FY2019Dec 31, 2019-$15.98M–
FY2018Dec 31, 2018-$954.32K–
FY2017Dec 31, 2017-$6.63K–
FY2016Dec 31, 2016-$1.00M–
FY2015Dec 31, 2015-$11.65M–
FY2014Dec 31, 2014-$3.97M–
FY2013Dec 31, 2013-$80.31K–
FY2012Dec 31, 2012-$89.57K–
FY2011Dec 31, 2011-$97.10K-116.6%
FY2010Dec 31, 2010$585.60K+414.9%
FY2009Dec 31, 2009$113.74K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$532.94K–
Q2 FY2026Jun 30, 2026-$378.83K–
Q1 FY2026Mar 31, 2026-$682.34K–
Q4 FY2025Dec 31, 2025-$893.55K–
Q3 FY2025Sep 30, 2025-$935.65K–
Q2 FY2025Jun 30, 2025-$840.98K–
Q1 FY2025Mar 31, 2025-$677.59K–
Q4 FY2024Dec 31, 2024-$1.53M-318.4%
Q3 FY2024Sep 30, 2024-$515.98K–
Q2 FY2024Jun 30, 2024-$517.82K–
Q1 FY2024Mar 31, 2024-$790.20K–
Q4 FY2023Dec 31, 2023$699.61K–
Q3 FY2023Sep 30, 2023-$667.50K–
Q2 FY2023Jun 30, 2023-$892.94K–
Q1 FY2023Mar 31, 2023-$720.28K–
Q4 FY2022Dec 31, 2022-$3.20M–
Q3 FY2022Sep 30, 2022-$588.48K–
Q2 FY2022Jun 30, 2022-$704.14K–
Q1 FY2022Mar 31, 2022-$715.56K–
Q4 FY2021Dec 31, 2021-$704.54K–
Q3 FY2021Sep 30, 2021-$771.20K–
Q2 FY2021Jun 30, 2021-$796.08K–
Q1 FY2021Mar 31, 2021-$721.35K–
Q4 FY2020Dec 31, 2020-$9.82M–
Q3 FY2020Sep 30, 2020-$1.31M–
Q2 FY2020Jun 30, 2020-$787.48K–
Q1 FY2020Mar 31, 2020-$2.57M–
Q4 FY2019Dec 31, 2019-$7.99M–
Q3 FY2019Sep 30, 2019-$6.36M–
Q2 FY2019Jun 30, 2019-$688.86K–
Q1 FY2019Mar 31, 2019-$946.92K–
Q4 FY2018Dec 31, 2018-$703.32K–
Q3 FY2018Sep 30, 2018-$180.49K–
Q2 FY2018Jun 30, 2018-$70.50K–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017-$4.97K–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017-$70.50K–
Q1 FY2017Mar 31, 2017-$1.67K–
Q4 FY2016Dec 31, 2016-$36.22K–

More CannaPharmaRx figures

See a number that looks wrong?